Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A 62-year-old woman is evaluated in the intensive care unit for new-onset toe pain. She was admitted 5 days ago for a massive pulmonary embolism and has been receiving a continuous intravenous unfractionated heparin infusion. Her temperature is 37.2°C (99.0°F), blood pressure is 138/86 mm Hg, and pulse is 98/min. Physical examination reveals dark purple discoloration and ischemic changes in the toes of her left foot. Laboratory studies show a platelet count of 88,000/mm³, a significant decrease from her admission platelet count of 250,000/mm³. A presumptive diagnosis of heparin-induced thrombocytopenia (HIT) with arterial thrombosis is made, and anti-platelet factor 4 (PF4) antibody testing is ordered.

Arrange the following pharmacologic management steps in the required chronological sequence according to standard treatment protocols for this condition.

  1. 1Discontinue the intravenous unfractionated heparin infusion
  2. 2Initiate an intravenous argatroban infusion
  3. 3Initiate oral warfarin therapy
  4. 4Discontinue the intravenous argatroban infusion

Cevap

The correct chronological sequence is to first discontinue the unfractionated heparin, then initiate an intravenous argatroban infusion, subsequently initiate oral warfarin therapy (only once platelets recover), and finally discontinue the intravenous argatroban infusion (after a sufficient overlap).
The management of HIT requires a strict pharmacological sequence. First, the inciting agent (unfractionated heparin) must be discontinued. Second, because HIT strongly activates platelets and the coagulation cascade, patients require immediate therapeutic anticoagulation with a non-heparin agent, such as a direct thrombin inhibitor (argatroban). Third, transition to a vitamin K antagonist (warfarin) must be delayed until the platelet count has recovered to at least 150,000/mm³. Initiating warfarin earlier can lead to a transient extreme hypercoagulable state due to the rapid depletion of Protein C, risking venous limb gangrene. Finally, argatroban is discontinued only after an overlap of at least 5 days with warfarin and a therapeutic INR for at least 24 hours.

Adım Adım Çözüm

1
Recognize the clinical presentation of Heparin-Induced Thrombocytopenia (HIT).
The patient has a significant drop in platelets occurring 5 days after heparin initiation, coupled with new arterial thrombosis (ischemic toes), yielding a high probability 4T score.
Accurate clinical identification dictates the immediate need for a specific, protocolized change in pharmacotherapy.
2
Identify the first pharmacologic intervention required.
Discontinue all heparin products immediately.
Halting exposure to the inciting drug stops the formation of new heparin-PF4-IgG immune complexes.
3
Determine the next necessary agent for this highly thrombotic state.
Initiate a non-heparin direct thrombin inhibitor (argatroban).
Patients with HIT are at extreme risk for new or extending thromboses and require immediate alternative anticoagulation.
4
Sequence the transition to long-term oral anticoagulation.
Initiate warfarin only after platelet recovery, followed later by the discontinuation of argatroban.
Early warfarin use depletes Protein C rapidly, risking venous limb gangrene. Argatroban must overlap warfarin for at least 5 days until the INR is therapeutic.

Anahtar Kavram

Chronological pharmacological management of Heparin-Induced Thrombocytopenia (HIT)
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru